1 / 26

גידולי בלוטת התריס

גידולי בלוטת התריס. ד"ר חגי מזא" ה כירורגיה אנדוקרינית מבואות כירורגיה שנה ד'. Indications for Surgery Benign. Benign: Compression symptoms: Dyspnea Dysphagia Hoarseness Hyperthyroidism: Toxic nodule Toxic MNG Graves’ disease Aesthetic concerns. Indications for Surgery Malignant.

sal
Download Presentation

גידולי בלוטת התריס

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. גידולי בלוטת התריס ד"ר חגי מזא"ה כירורגיה אנדוקרינית מבואות כירורגיה שנה ד'

  2. Indications for SurgeryBenign • Benign: • Compression symptoms: • Dyspnea • Dysphagia • Hoarseness • Hyperthyroidism: • Toxic nodule • Toxic MNG • Graves’ disease • Aesthetic concerns

  3. Indications for SurgeryMalignant • Papillary thyroid cancer(PTC) • Follicular thyroid cancer (FTC) • Medullary thyroid cancer (MTC) • Anaplastic thyroid cancer (ATC) • Lymphoma • Mets

  4. Thyroid Cancer • Most common malignancy of the endocrine system • Increasing incidence • 2% of all new cancer diagnoses • Over 44,000/y expected to be diagnosed in the US

  5. Thyroid nodules • Very common • 5% have palpable thyroid nodules • ~50% have thyroid nodules on US • Only 5% malignant

  6. Case 1 • 24 YOF • Upon shaving identified a 3 cm mass in her front neck

  7. Case 1 • Physician – • History • Thyroid function (hyper/hypo) • Risk factors – family history, radiation history • Physical examination • Nodule • Other thyroid nodules • Cervical lymph nodes • Labs • Thyroid function tests

  8. Case 1 • Radiology – Ultrasound: • Most accurate imaging for thyroid nodules • Nodule location • Nodule size (3 dimensions) • Nodule growth • Nodule features: • Microcalcifications • Solid • Lack of Halo / hypoechoic rim • Taller more than wide • Irregular margins • Hypervascular • Hypoechoic • Local invasion

  9. Case 1 • US guided FNAB • Limited to cells (no vascular or capsular invasion) • Equivocal diagnosis

  10. Case 1 • FNAB result – Benign • Management: • Observation • Repeat US • Repeat FNAB (?)

  11. Case 2 • FNAB result – Malignant • Well-differentiated thyroid cancer • Well-differentiated thyroid cancer: • Papillary (PTC) or Follicular (FTC) • Most common (>90% of thyroid cancers) • Very good prognosis (>95% 10YS)

  12. Well-differentiated thyroid cancer Staging ≥ 45 y: • Stage 1 – T< 2cm • Stage 2 – T 2-4cm • Stage 3 – T>4cm, N1a • Stage 4 – M1, N1b < 45 y: • Stage 1 – any T, any N • Stage 2 – M1

  13. Case 2Well-differentiated thyroid cancer • Management: • Depends on size and LN status • ≤ 1 cm – Lobectomy • > 1 cm – total thyroidectomy • Consider prophylactic CLND

  14. Case 2Well-differentiated thyroid cancer • Lateral LND – • FNAB proven involved LN

  15. Case 2Well-differentiated thyroid cancer • Adjuvant therapy: • Selective RAI • TSH suppression • Follow up: • P/E, Tg, Neck US • Up to 30% will require redo surgery (cervical lymph nodes)

  16. Case 3Medullary thyroid cancer • 3-5% of all thyroid cancers • Parafollicular C cells • 75% sporadic • 25% hereditary • MEN IIA (MTC, pheochromococytoma, primary hyperparathyroidism) • MEN IIB (MTC, pheochromocytoma, neurogangliomas) • Familial MTC (non-MEN II)

  17. Case 3Medullary thyroid cancer • Physician – • History • Thyroid function (hyper/hypo) • Risk factors – family history, radiation history • Other endocrinopathies • Physical examination • Nodule • Other thyroid nodules • Cervical lymph nodes • Labs • Thyroid function tests • Calcitonin / CEA • Genetic counseling

  18. Case 3Medullary thyroid cancer • Radiology • Ultrasound – neck • CT – chest abdomen for mets • Management – aggressive!!! • Total thyroidectomy • Central lymph node dissection • Selective lateral lymph node dissection • Tumor size, preoperative US, calcitonin level

  19. Case 3Medullary thyroid cancer • Adjuvant therapy – • No RAI, No TSH suppression • Clinical trials drugs • Follow up – • CEA, calcitonin • Neck US • Prognosis • 75-85% overall 10YS

  20. Case 3Medullary thyroid cancer • Prophylactic surgery • Mutation based: • Level 3 (Highest risk, 883, 918, 922) – • Within age 6-12 months • Level 2 (Higher risk, 611, 618, 620, 634) – • By the age of 5y • Level 3 (High risk, 609, 630, 768, 790, 791, 804, 891) – • By the age of 10y

  21. Case 4Other thyroid cancers • Anaplastic thyroid cancer: • 1% of thyroid cancers • Undifferentiated thyroid cancer • Usually not resectable • Very poor prognosis (5% 5YS) • Thyroid Lymphoma • 1-2% of thyroid cancers • No surgical treatment • CHOP / radiation

  22. Case 5Follicular lesion • Follicular lesion / neoplasm • 15-30% malignancy • Surgeon • Actually has to talk to the patient!! • Options – Lobectomy / total thyroidectomy • Lobectomy – • decreased complications • may not require thyroid replacement • may need ANOTHER surgery if malignant on pathology

  23. ThyroidectomyComplications • Immediate / early • Bleeding • 1-2%, mostly no intervention required • Hematoma requiring urgent drainage – rare • Transient hypocalcemia • Only following total thyroidectomy • 10-20% • Transient hoarseness • 10-20%

  24. ThyroidectomyComplications • Long term • Permanent hypocalcemia • 2-4% • Permanent hoarseness • 1-2% • Permanent hormone replacement therapy • (following thyroidectomy)

More Related